Document Detail


CD133+ cancer stem cells in lung cancer.
MedLine Citation:
PMID:  23276935     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lung cancer is the most preventable cancer worldwide but has a poor prognosis. Recent advances in the study of lung cancer stem cell (CSC) populations has led to a growing recognition of the central importance of cells with stem cell-like properties in lung tumorigenesis. High number of CD133+ cells is associated with the maintenance, metastasis and drug-resistance of lung cancer. CD133 serves as a stemness biomarker for CD133+ CSCs, which have been found in lung cancer tissues. This article reviews the major studies supporting the existence and importance of CD133+ CSCs in the maintenance, metastasis and drug resistance of lung cancer. Continued research in the field of CD133+ CSCs biology is vital, as ongoing efforts promise to yield new prognostic and therapeutic targets.
Authors:
Shuang Wang; Zhen Ye Xu; Li Fang Wang; Wan Su
Related Documents :
23340175 - Synergistic anticancer activity of hs-173, a novel pi3k inhibitor in combination with s...
24959385 - Anticancer drug fl118 is more than a survivin inhibitor: where is the achilles' heel of...
19996275 - Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells.
24856665 - Oleanolic acid induces metabolic adaptation in cancer cells by activating amp-activated...
21438985 - Incidence of prostate cancer in sri lanka using cancer registry data and comparisons wi...
21655925 - Watchful waiting and active surveillance approach in patients with low risk localized p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  447-53     Citation Subset:  IM    
Affiliation:
Department of Oncology Part II, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Xuhui District, Shanghai City, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / pathology
Antigens, CD / physiology*
Carcinoma, Non-Small-Cell Lung / pathology
Cell Transformation, Neoplastic / pathology*
Glycoproteins / physiology*
Humans
Lung Neoplasms / pathology*
MicroRNAs / physiology
Neoplasm Metastasis / prevention & control
Neoplastic Stem Cells / pathology*
Octamer Transcription Factor-3 / genetics
Peptides / physiology*
Prognosis
Small Cell Lung Carcinoma / pathology
Tumor Markers, Biological
Chemical
Reg. No./Substance:
0/AC133 antigen; 0/Antigens, CD; 0/Glycoproteins; 0/MIRN145 microRNA, human; 0/MicroRNAs; 0/Octamer Transcription Factor-3; 0/Peptides; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MicroRNA in the molecular mechanism of the circadian clock in mammals.
Next Document:  Biological significance and targeting of c-Met tyrosine kinase receptor in cancer.